jarun011 The U.S. FDA has expanded the indication for Novartis' ( NYSE: NVS ) Scemblix (asciminib) as a first-line treatment for chronic myeloid leukemia.
The accelerated approval is for adults with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. The Swiss pharma noted that.
